Guinness Asset Management LTD lessened its position in AbbVie Inc. (NYSE:ABBV – Free Report) by 3.1% during the 4th quarter, Holdings Channel reports. The firm owned 1,173,180 shares of the company’s stock after selling 37,113 shares during the quarter. AbbVie makes up about 4.4% of Guinness Asset Management LTD’s investment portfolio, making the stock its 5th biggest position. Guinness Asset Management LTD’s holdings in AbbVie were worth $269,981,000 as of its most recent filing with the SEC.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the 3rd quarter valued at $26,000. Westend Capital Management LLC acquired a new stake in shares of AbbVie in the 4th quarter valued at $29,000. Texas Capital Bancshares Inc TX acquired a new stake in shares of AbbVie in the 3rd quarter valued at $31,000. Legacy Wealth Managment LLC ID boosted its stake in shares of AbbVie by 115.9% in the 4th quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares in the last quarter. Finally, WestEnd Advisors LLC boosted its stake in shares of AbbVie by 160.4% in the 4th quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.
Analyst Ratings Changes
A number of research firms recently issued reports on ABBV. Morgan Stanley lifted their price target on AbbVie from $270.00 to $278.00 and gave the company an “overweight” rating in a report on Thursday, April 30th. Wall Street Zen cut AbbVie from a “strong-buy” rating to a “buy” rating in a report on Sunday, May 17th. Guggenheim reaffirmed a “buy” rating and issued a $249.00 price target on shares of AbbVie in a report on Friday, May 1st. Piper Sandler lifted their price target on AbbVie from $294.00 to $298.00 and gave the company an “overweight” rating in a report on Thursday, May 14th. Finally, Barclays began coverage on AbbVie in a report on Thursday, February 19th. They issued an “overweight” rating and a $275.00 price target for the company. Three analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.
Insider Activity
In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total transaction of $5,147,630.00. Following the completion of the sale, the executive vice president directly owned 38,137 shares of the company’s stock, valued at approximately $8,771,510. The trade was a 36.98% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Ryan Purdue sold 5,230 shares of the business’s stock in a transaction dated Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the sale, the senior vice president directly owned 2,654 shares of the company’s stock, valued at $619,868.24. This represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders own 0.06% of the company’s stock.
AbbVie Stock Up 0.7%
AbbVie stock opened at $216.02 on Friday. The stock has a 50-day simple moving average of $208.72 and a 200 day simple moving average of $219.68. AbbVie Inc. has a 12-month low of $181.71 and a 12-month high of $244.81. The stock has a market capitalization of $381.66 billion, a price-to-earnings ratio of 106.41, a P/E/G ratio of 0.74 and a beta of 0.32.
AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.59 by $0.06. The business had revenue of $15 billion during the quarter, compared to analysts’ expectations of $14.72 billion. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The firm’s revenue for the quarter was up 12.4% compared to the same quarter last year. During the same period in the previous year, the business posted $2.46 earnings per share. As a group, sell-side analysts anticipate that AbbVie Inc. will post 14.3 EPS for the current year.
AbbVie News Roundup
Here are the key news stories impacting AbbVie this week:
- Positive Sentiment: AbbVie received a positive opinion from the European Medicines Agency’s CHMP for MAVIRET in acute hepatitis C, a potential label expansion that could broaden the drug’s commercial opportunity in Europe. Article Title
- Positive Sentiment: Allergan Aesthetics, an AbbVie company, also secured a positive CHMP opinion for Boey, adding another potential European growth catalyst for AbbVie’s aesthetics business. Article Title
- Positive Sentiment: AbbVie highlighted new oncology data at ASCO 2026, signaling continued momentum across its next-generation cancer pipeline and supporting longer-term growth expectations. Article Title
- Positive Sentiment: Analyst and media commentary remained constructive, with pieces calling AbbVie a strong dividend pick and a long-term buy, which can reinforce investor confidence in the stock. Article Title
- Neutral Sentiment: AbbVie plans 85 summer layoffs in California tied to its Allergan Aesthetics unit, a cost-cutting move that may draw attention but is not large enough on its own to materially change the investment case. Article Title
AbbVie Profile
AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.
AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.
Featured Stories
- Five stocks we like better than AbbVie
- MarketBeat Week in Review – 05/18 – 05/22
- SpaceX IPO: Opportunity? Or the Ultimate Hype Trade?
- CAVA Group’s Stock Looks Delicious After Strong Earnings
- Lowe’s Finds Support at $215 After Q1 Earnings Sell-Off
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
